Fig. 1From: Serum superoxide dismutase level is a potential biomarker of disease prognosis in patients with HEV-induced liver failureKaplan–Meier analyses for survival and plasma SOD levels in HEV-induced liver failure patients. A HEV-ALF patients showed lower mortality rate than HEV-ACLF patients; B Plasma SOD levels were lower in HEV-ALF patients compared to HEV-ACLF patients. *P < 0.05, **P < 0.01Back to article page